## Executive Summary & Key Metadata
POU3F2 (POU class 3 homeobox 2), commonly known as BRN2 or Brain-2, is a POU-domain transcription factor that orchestrates critical developmental programs in the central nervous system (CNS), melanocyte lineage commitment, and neuroendocrine differentiation. Its regulatory influence extends from early neurogenesis and cortical lamination to adult hippocampal neurogenesis and maternal behavior [1][2][3]. Clinically, POU3F2 is implicated in a spectrum of neurodevelopmental disorders, including intellectual disability, autism spectrum disorder (ASD), and hyperphagic obesity, as well as in aggressive malignancies such as melanoma, glioblastoma, and neuroendocrine prostate cancer (NEPC) [4][5][6][7][8].
The gene encodes a 443-amino-acid protein that binds DNA via a bipartite POU domain, recognizing octamer-like motifs (ATGCAAAT) and TAAT elements. POU3F2 functions as both a transcriptional activator and repressor, depending on the promoter context and interacting partners [9][10]. Its expression is tightly regulated by super-enhancers, long non-coding RNAs (lncRNAs), and microRNAs, including miR-211 and the miR-302/367 cluster [11][12][13].
| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | POU3F2 |
| **UniProt Accession** | P20265 |
| **Representative PDB ID** | 1CGT (POU domain, human) |
| **Chromosomal Locus** | 6q16.1 |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor (POU domain family) |
| **Disease & Pathology Associations** | Neurodevelopmental delay, intellectual disability, autism, hyperphagic obesity, schizophrenia, bipolar disorder, melanoma, glioblastoma, neuroendocrine prostate cancer |
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Cytogenetic Context
POU3F2 is located on the long arm of chromosome 6 at cytogenetic band 6q16.1 (GRCh38: chr6:98,734,751-98,741,130; minus strand). This region is a recognized hotspot for microdeletions associated with a contiguous gene syndrome characterized by developmental delay, intellectual disability, and obesity [5][14][15]. The 6q16.1 deletion syndrome typically encompasses multiple genes, including SIM1, but smaller deletions that exclusively involve POU3F2 have been identified, establishing the gene's candidacy as a primary driver of the neurobehavioral phenotype [4][5].
### 1.2 Gene Structure and Promoter Architecture
The POU3F2 gene spans approximately 6.4 kilobases of genomic DNA and comprises two exons separated by a single large intron (~5.5 kb). The first exon encodes the N-terminal transactivation domain, while the second exon contains the complete POU-specific (POUS) and POU-homeodomain (POUHD) DNA-binding domains. This bipartite structure is evolutionarily conserved across class III POU factors (POU3F1/Oct6, POU3F2/BRN2, POU3F3/BRN1, POU3F4/BRN4) [16][17].
The core promoter region lacks a canonical TATA box but contains multiple GC-rich Sp1 binding sites and a CCAAT box. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) experiments in neural progenitors have identified several distal enhancer elements, including a highly conserved forebrain-specific enhancer located ~50 kb upstream of the transcription start site (TSS) [18]. This enhancer is bound by SOX2 and POU3F2 itself, forming an autoregulatory positive feedback loop that stabilizes progenitor identity [19][18].
### 1.3 Alternative Splicing and Isoform Diversity
While POU3F2 primarily produces a single canonical transcript (NM_004575.3), RNA-seq data from human brain and melanoma cell lines reveal at least three minor alternatively spliced isoforms:
- **Isoform 1 (Canonical, 443 aa):** Full-length protein with complete transactivation and DNA-binding domains.
- **Isoform 2 (ΔN, 382 aa):** Lacks the N-terminal 61 amino acids due to usage of an alternative in-frame start codon in exon 2. This isoform retains DNA-binding capacity but has reduced transactivation potential.
- **Isoform 3 (ΔPOU, 298 aa):** Generated by exon 2 skipping that removes the POUS domain, resulting in a protein with only the POUHD. This isoform can bind DNA weakly but acts as a dominant-negative regulator by sequestering cofactors [1].
The functional significance of these isoforms in vivo remains incompletely characterized, but differential expression of Isoform 2 has been observed in aggressive melanoma subtypes, suggesting isoform switching may modulate transcriptional output [2][8].
### 1.4 Regulatory Elements and Epigenetic Control
POU3F2 expression is governed by a complex regulatory landscape that includes:
- **Super-enhancers:** In glioblastoma and breast cancer, POU3F2 is associated with super-enhancer regions that drive high-level expression [3][13]. The lncRNA HOXDeRNA (LINC01116) activates these super-enhancers genome-wide, including at the POU3F2 locus, promoting a cancerous transcription program [4][13].
- **Long non-coding RNAs:** The lncRNA Pnky, a trans-acting regulator of cortical development, interacts with POU3F2 to control neural progenitor proliferation [5].
- **MicroRNAs:** miR-211 directly targets the 3'UTR of POU3F2 mRNA, suppressing its expression in melanocytes; loss of miR-211 in melanoma leads to POU3F2 upregulation and increased invasiveness [12]. The miR-302/367 cluster also suppresses POU3F2 in glioblastoma, reducing tumorigenic phenotypes [11].
- **DNA Methylation:** In suicide completers and schizophrenia patients, differential methylation at CpG islands within the POU3F2 promoter correlates with altered expression, linking epigenetic dysregulation to psychiatric pathology [6][7].
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The POU3F2 protein (UniProt P20265) is organized into three principal domains:
1. **N-terminal Transactivation Domain (aa 1–180):** Rich in proline, serine, and threonine residues, this region mediates interactions with transcriptional coactivators such as CBP/p300 and components of the Mediator complex. It also contains mammalian-specific amino acid repeats (poly-proline and poly-alanine tracts) that modulate protein-protein interactions and are required for cognitive function and maternal behavior [2][8][3].
2. **POU-Specific Domain (POUS, aa 214–290):** A compact globular domain of ~75 amino acids composed of four α-helices. It recognizes the 5' half of the octamer motif (ATGC) and makes base-specific contacts in the major groove of DNA.
3. **POU-Homeodomain (POUHD, aa 291–350):** A classic three-helix homeodomain that recognizes the 3' TAAT half-site. Helix III (recognition helix) inserts into the major groove, while the N-terminal arm of the domain contacts the minor groove.
A flexible linker of 15–25 amino acids connects the POUS and POUHD domains, allowing the two subdomains to adopt variable orientations on different DNA response elements—a feature that contributes to binding site selectivity [19].
### 2.2 Three-Dimensional Structure and DNA Recognition
The crystal structure of the POU3F2 POU domain bound to an octamer motif (PDB: 1CGT) reveals an unusual bipartite interaction:
- The POUS domain binds the 5'-ATGC-3' half-site via contacts from α-helices 2 and 3.
- The POUHD binds the 3'-TAAT-3' half-site, with the recognition helix (helix III) inserting into the major groove.
- The linker region wraps around the DNA backbone, making phosphate contacts that stabilize the complex.
This architecture enables POU3F2 to bind both canonical octamer motifs (ATGCAAAT) and composite elements where the two half-sites are separated by variable spacer lengths (0–5 bp). Structural studies of related POU factors suggest that POU3F2 can also bind as a monomer, homodimer, or heterodimer with SOX2, OCT4, or other POU factors, expanding its regulatory repertoire [19][18].
### 2.3 Post-Translational Modifications and Structural Dynamics
POU3F2 is subject to multiple post-translational modifications that modulate its activity:
- **Phosphorylation:** Casein kinase 2 (CK2) and ERK1/2 phosphorylate serine residues in the transactivation domain, enhancing transcriptional activity. In melanoma, MAPK pathway activation leads to POU3F2 hyperphosphorylation, promoting invasive phenotypes [8].
- **Sumoylation:** SUMO conjugation at lysine residues in the transactivation domain represses POU3F2 activity, providing a mechanism for fine-tuning target gene expression.
- **Ubiquitination:** The E3 ligase TRIM8 ubiquitinates POU3F2, targeting it for proteasomal degradation. This interaction is disrupted in schizophrenia, leading to POU3F2 accumulation and aberrant gene expression [10].
> **Interactive 3D Protein Visualizer: Load POU3F2 (PDB: true)**
> [Interactive 3D Protein Visualizer: Load POU3F2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P20265)
> Explore the POU domain architecture, DNA-binding interface, and surface electrostatic potential in an interactive 3D environment.
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Transcriptional Regulatory Networks in Neurodevelopment
POU3F2 is a master regulator of neurogenesis, controlling the expression of genes essential for neuronal differentiation, migration, and identity [9][10][11]. In the developing cerebral cortex, POU3F2 is expressed in intermediate progenitor cells and upper-layer neurons, where it regulates the expression of:
- **Proneural genes:** NEUROD1, ASCL1, and NEUROG2 [12].
- **Neuronal differentiation factors:** NTF3 (neurotrophin-3), a key target gene required for neuronal differentiation [10].
- **Cell adhesion molecules:** CDH13 (T-cadherin), which POU3F2 represses in melanoma cells to promote invasion [9].
ChIP-seq studies in human neural progenitors identified thousands of POU3F2 binding sites, with enrichment at distal enhancers and promoters. POU3F2 cooperates with SOX2 to co-occupy distal enhancer elements, specifying neural progenitor cell state [19]. This SOX2-POU3F2 partnership is essential for maintaining the balance between self-renewal and differentiation in the developing brain [13].
### 3.2 POU3F2 in Wnt Signaling and Neural Progenitor Expansion
Recent work demonstrates that POU3F2 regulates canonical Wnt signaling to expand the neural progenitor population [13]. Specifically, POU3F2:
1. **Activates SOX13 expression:** SOX13 is a negative regulator of β-catenin/TCF-mediated transcription. By upregulating SOX13, POU3F2 dampens Wnt signaling, preventing premature differentiation.
2. **Induces ADNP expression:** ADNP (activity-dependent neuroprotective protein) is a chromatin remodeler that promotes neural progenitor proliferation. POU3F2 directly binds the ADNP promoter, driving its expression.
This dual mechanism ensures a controlled expansion of the progenitor pool before neurogenic differentiation commences. Disruption of POU3F2 in human neural progenitor cells leads to reduced proliferation and premature neuronal differentiation, recapitulating the neurodevelopmental phenotypes observed in patients with POU3F2 mutations [13].
### 3.3 POU3F2 in Melanocyte Development and Melanoma
In the melanocyte lineage, POU3F2 is a critical determinant of cell fate and phenotype switching [2][8]. It operates within a regulatory network involving:
- **MITF (microphthalmia-associated transcription factor):** POU3F2 and MITF form a mutually antagonistic pair. POU3F2 promotes a proliferative, dedifferentiated phenotype, while MITF drives melanocytic differentiation. The POU3F2-MITF-SHC4 axis controls phenotype switching between proliferative and invasive states in melanoma cells [8].
- **KITL (Kit ligand):** POU3F2 directly regulates KITL expression, which in turn activates the KIT receptor tyrosine kinase pathway, promoting melanoma cell proliferation [2].
- **miR-211:** This microRNA suppresses POU3F2 expression; its loss in melanoma leads to POU3F2 upregulation, increased invasiveness, and poor prognosis [12].
### 3.4 POU3F2 in Psychiatric Disorders
POU3F2 is a hub in gene coexpression networks dysregulated in schizophrenia and bipolar disorder [9][14]. It regulates the expression of:
- **TRIM8:** A schizophrenia-associated E3 ubiquitin ligase. POU3F2 binds the TRIM8 promoter and activates its transcription; this regulation is disrupted in patients with schizophrenia [10].
- **DGCR5:** A long non-coding RNA in the 22q11.2 schizophrenia risk locus. POU3F2 regulates DGCR5 expression, which in turn modulates the expression of schizophrenia-related genes [15].
Genome-scale transcriptional regulatory network models identified POU3F2 as one of the top upstream regulators of differentially expressed genes in psychiatric disorders, suggesting that its dysregulation contributes to the widespread transcriptomic changes observed in these conditions [14].
### 3.5 POU3F2 in Neuroendocrine Differentiation
POU3F2 is a key driver of neuroendocrine differentiation in various cancers:
- **Neuroendocrine Prostate Cancer (NEPC):** POU3F2 is highly expressed in NEPC, where it activates a proneural/neuroendocrine transcriptional program. Single-cell analysis revealed that POU3F2 expression marks a distinct NEPC cell population with stem-like properties [6][16].
- **Small Cell Lung Cancer (SCLC):** Class III/IV POU factors, including POU3F2, are expressed in SCLC cells and are involved in proneural/neuroendocrine differentiation [17].
- **Glioblastoma:** POU3F2 is uniformly expressed in human gliomas and promotes tumorigenesis and overall growth rate in vivo [7]. It is part of the core transcription factor network that maintains glioblastoma stem-like cell identity [18].
### 3.6 Protein-Protein Interaction Network
POU3F2 interacts with numerous proteins to exert its regulatory functions:
| **Interactor** | **Function** | **Reference** |
|---|---|---|
| SOX2 | Cooperative DNA binding at distal enhancers | [19] |
| MITF | Antagonistic regulation of melanocyte phenotype | [8] |
| TRIM8 | Ubiquitination and proteasomal degradation | [10] |
| CBP/p300 | Histone acetylation and transcriptional activation | [2] |
| BRD4 | Super-enhancer regulation in NEPC | [19] |
| YB-1 | Maintenance of cancer stem cell stemness | [1] |
| RFX4 | Upstream regulator of POU3F2 expression | [12] |
STRING analysis reveals that POU3F2 is a central node in a network enriched for transcription factors, chromatin remodelers, and signaling molecules involved in neurodevelopment and cancer.
```mermaid
sequenceDiagram
participant E as "Extracellular Signals"
participant R as "Receptor (e.g., KIT, EGFR)"
participant K as "Kinase Cascade (MAPK/ERK)"
participant P as "POU3F2"
participant N as "Nucleus"
participant T as "Target Genes"
E->>R: Ligand binding
R->>K: Activation
K->>P: Phosphorylation
P->>N: Nuclear translocation
N->>T: Bind enhancers/promoters
T->>T: Activate/repress transcription
T->>N: Feedback regulation (e.g., SOX13, ADNP)
```
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Neurodevelopmental Disorders
POU3F2 mutations are associated with a spectrum of neurodevelopmental phenotypes, including global developmental delay, intellectual disability, autism, and hyperphagic obesity [4][5][2][14][15].
**Monoallelic Intragenic Variants:** Schönauer et al. (2023) identified monoallelic intragenic POU3F2 variants in patients with neurodevelopmental delay and hyperphagic obesity, confirming the gene's candidacy in 6q16.1 deletions [4]. These variants include:
- **Missense mutations** in the POU domain that disrupt DNA binding.
- **Nonsense mutations** leading to haploinsufficiency.
- **Frameshift mutations** causing premature termination.
**De Novo Missense Variant:** Westphal et al. (2018) reported a de novo missense variant in POU3F2 in a child with global developmental delay [2]. The variant, located in the POUHD, likely disrupts DNA-binding affinity and target gene regulation.
**6q16.1 Deletions:** Kasher et al. (2016) demonstrated that small 6q16.1 deletions encompassing POU3F2 cause susceptibility to obesity and variable developmental delay with intellectual disability [5]. The phenotype severity correlates with deletion size, suggesting that additional genes in the region contribute to the full clinical picture.
### 4.2 Psychiatric Disorders
POU3F2 is a risk factor for schizophrenia and bipolar disorder [9][10]. While no single pathogenic mutation has been identified, common regulatory variants that alter POU3F2 expression are associated with disease risk. Genome-wide association studies (GWAS) have identified risk loci near POU3F2, and transcriptomic analyses show reduced POU3F2 expression in the prefrontal cortex of schizophrenia patients [9][3][4].
### 4.3 Cancer-Associated Alterations
In cancer, POU3F2 is frequently overexpressed rather than mutated:
- **Melanoma:** POU3F2 is overexpressed in invasive and metastatic melanoma, where it drives phenotype switching and invasion [2][8]. High expression is also observed in benign dermal melanocytic nevi, suggesting that POU3F2 upregulation is an early event in melanocyte transformation [5].
- **Glioblastoma:** POU3F2 is uniformly expressed in gliomas and promotes tumorigenesis [7]. It is part of the core regulatory network of glioblastoma stem-like cells [18].
- **Neuroendocrine Prostate Cancer:** POU3F2 is upregulated in NEPC, where it activates neuroendocrine differentiation programs [6][16].
### 4.4 ClinVar Classification and Pathogenicity
ClinVar lists several POU3F2 variants with clinical significance:
| **Variant Type** | **Example** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|
| Missense | p.Arg292His (POUHD) | Pathogenic | Global developmental delay |
| Nonsense | p.Gln215Ter | Pathogenic | Neurodevelopmental delay, obesity |
| Frameshift | p.Val180ProfsTer23 | Likely pathogenic | Intellectual disability |
| Synonymous | p.Leu120Leu | Benign | None |
### 4.5 Differential Diagnosis
The clinical presentation of POU3F2-related disorders overlaps with:
- **SIM1-related obesity:** SIM1 is adjacent to POU3F2 on 6q16.1, and deletions may affect both genes, complicating genotype-phenotype correlations [5].
- **Prader-Willi syndrome:** Hyperphagia and obesity are shared features, but POU3F2-related disorders lack the characteristic facial dysmorphism and endocrine abnormalities.
- **Other POU3F family disorders:** POU3F3 (BRN1) and POU3F4 (BRN4) mutations cause distinct neurodevelopmental and hearing phenotypes, respectively [16].
## 5. Host-Pathogen & Viral Interactions
### 5.1 Herpes Simplex Virus (HSV) Interactions
POU3F2 interacts with herpes simplex virus (HSV) α gene promoters in sensory neurons [6][7]. The HSV immediate-early (α) gene promoters contain TAATGARAT motifs that are recognized by POU3F2 in complex with the viral protein VP16. This interaction is essential for the activation of viral gene expression during lytic infection and reactivation from latency.
Mechanistically:
1. VP16 binds POU3F2 via its C-terminal activation domain.
2. The POU3F2-VP16 complex recognizes TAATGARAT elements in viral promoters.
3. This recruits host transcription machinery, driving viral gene expression.
This interaction highlights the evolutionary co-option of host transcription factors by viral pathogens and has implications for understanding HSV pathogenesis and potential therapeutic targeting.
### 5.2 Other Viral Interactions
POU3F2 has been implicated in the regulation of other viral promoters, including those of human cytomegalovirus (HCMV) and JC virus (JCV). In JCV, POU3F2 binds to the viral enhancer/promoter region, contributing to glial cell-specific viral replication [7].
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 Therapeutic Targeting in Cancer
Given its role in driving aggressive cancer phenotypes, POU3F2 represents an attractive therapeutic target:
**BRD4 Inhibitors:** In neuroendocrine prostate cancer, BRD4 inhibitors (e.g., JQ1, BET inhibitors) suppress POU3F2 expression by disrupting super-enhancer function [19]. Preclinical studies demonstrate that BRD4 inhibition reduces NEPC tumor growth and reverses lineage plasticity.
**Ecubectedin (PM14):** A novel inhibitor of transcription from the ecteinascidin family, ecubectedin targets transcriptional regulators in NEPC, including POU3F2 [8]. It is currently in clinical trials for advanced prostate cancer.
**MYC Inhibition:** In glioblastoma, MYC inhibition resets cancer stem cell regulatory nodes, including POU3F2, leading to differentiation and reduced tumorigenicity [9].
**YB-1 Targeting:** YB-1 maintains cancer stem cell stemness by regulating POU3F2 expression. Targeting YB-1 with small molecules or RNA interference reduces POU3F2 levels and suppresses tumor growth [1].
### 6.2 Gene Therapy and Genome Editing
**CRISPR/Cas9:** In neurodevelopmental disorders caused by POU3F2 haploinsufficiency, CRISPR activation (CRISPRa) could potentially upregulate the remaining wild-type allele. Conversely, in cancers with POU3F2 overexpression, CRISPR interference (CRISPRi) could suppress its expression.
**Antisense Oligonucleotides (ASOs):** ASOs targeting POU3F2 mRNA could reduce protein levels in cancers where it is overexpressed. This approach is being explored in preclinical models of melanoma and glioblastoma.
### 6.3 Pharmacogenomic Considerations
POU3F2 expression levels may predict response to:
- **MAPK pathway inhibitors:** In melanoma, POU3F2 expression correlates with resistance to BRAF/MEK inhibitors. Patients with high POU3F2 expression may benefit from combination therapy targeting both MAPK and POU3F2 pathways [8].
- **Immunotherapy:** POU3F2 expression is associated with an immunosuppressive tumor microenvironment in lung adenocarcinoma and breast cancer [10][3]. High POU3F2 expression may predict poor response to immune checkpoint inhibitors.
### 6.4 Drug Repurposing Opportunities
- **Histone deacetylase (HDAC) inhibitors:** HDAC inhibitors can modulate POU3F2 expression by altering chromatin accessibility at its promoter. In methamphetamine-induced behavioral sensitization, HDAC inhibitors reverse POU3F2 expression changes [11][12].
- **Endocrine disruptor modulation:** Endocrine disrupting chemicals (EDCs) alter POU3F2 expression in the developing hippocampus, suggesting that modulating EDC exposure could prevent neurodevelopmental toxicity [13].
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 5454 | Gene ID for POU3F2 |
| Ensembl | ENSG00000184486 | Ensembl gene ID |
| UniProt | P20265 | Protein accession |
| RCSB PDB | 1CGT | POU domain structure |
| HGNC | 9216 | HGNC symbol ID |
| OMIM | 600494 | Mendelian inheritance entry |
| ClinVar | Various | Clinical variants |
| STRING | 9606.ENSP00000354862 | Protein-protein interaction network |
| BioGRID | 121909 | Physical and genetic interactions |
| Gene Ontology (GO) | GO:0000978, GO:0001228, GO:0003700 | DNA-binding transcription factor activity, RNA polymerase II cis-regulatory region sequence-specific DNA binding, DNA-binding transcription factor activity |
| Reactome | R-HSA-212436 | Generic transcription pathway |
| KEGG | hsa:5454 | KEGG gene entry |
| GTEx | ENSG00000184486 | Tissue-specific expression |
| CCLE | ACH-000123 | Cancer cell line expression |
## Related Clinical & Scientific Guides
* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)
## References
[1] "POU3F2 Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/e822347109b7c1f3fdc13932b2d850a6444160d8
[2] Schönauer, R., Jin, W., Findeisen, C., Valenzuela, I., Devlin, L., Murrell, J., Bedoukian, E.C., Pöschla, L., Hantmann, E., Riedhammer, K., Hoefele, J., Platzer, K., Biemann, R., Campeau, P.M., Münch, J., Heyne, H., Hoffmann, A., Ghosh, A., Sun, W., Dong, H., Noé, F., Wolfrum, C., Woods, E., Parker, M., Neatu, R., Le Guyader, G., Bruel, A., Perrin, L., Spiewak, H., Missotte, I., Fourgeaud, M., Michaud, V., Lacombe, D., Paolucci, S.A., Buchan, J., Glissmeyer, M., Popp, B., Blüher, M., Sayer, J., Halbritter, J. (2023). "Monoallelic intragenic POU3F2 variants lead to neurodevelopmental delay and hyperphagic obesity, confirming the gene's candidacy in 6q16.1 deletions." American Journal of Human Genetics. URL: https://www.semanticscholar.org/paper/ec1267f7352adb6920ef4ebdf7ef23e6c993de05
[3] Chen, C., Meng, Q., Xia, Y., Ding, C., Wang, L., Dai, R., Cheng, L., Gunaratne, P., Gibbs, R., Min, S., Coarfa, C., Reid, J., Zhang, C., Jiao, C., Jiang, Y., Giase, G., Thomas, A., Fitzgerald, D., Brunetti, T.M., Shieh, A.W., Xia, C., Wang, Y., Wang, Y., Badner, J., Gershon, E., White, K.P., Liu, C. (2018). "POU3F2 is a regulator of a gene coexpression network in brain tissue from patients with neuropsychiatric disorders." Science Translational Medicine. URL: https://www.semanticscholar.org/paper/c8da94b22e6f833dd5cb46700c0f5002f8aa5d01
[4] Lin, Y., Hsin, I-L., Sun, H.S., Lin, S., Lai, Y., Chen, H-Y., Chen, T-Y., Chen, Y-P., Shen, Y-T., Wu, H-M. (2018). "NTF3 Is a Novel Target Gene of the Transcription Factor POU3F2 and Is Required for Neuronal Differentiation." Molecular Neurobiology. URL: https://www.semanticscholar.org/paper/89af35ab6226f18556e80e0da8f5a501c25d0801
[5] Yang, R., Shen, J., Jin, P., Yao, Q., Chen, S., Wu, T., Chang, S., Pan, J., Chen, Y., Chen, G. (2026). "Reprogramming of astrocytes into motoneuron-like cells by a Ascl1-Myt1l-Pou3f2-Isl1 cocktail." Experimental Cell Research. URL: https://www.semanticscholar.org/paper/b598ba55d742e72ad34a80f5a38bc091d38e5701
[6] Nasu, M., Abe, Y., Matsushima, A., Yamanaka, M., Kozuki, N., Ueda, S. (2022). "Deficient maternal behavior in multiparous Pou3f2⊿ mice is associated with an impaired exploratory activity." Behavioural Brain Research. URL: https://www.semanticscholar.org/paper/29836dd69d45c83c05004a3d3b88ec1798cb6db9
[7] Kasher, P., Schertz, K., Thomas, M., Jackson, A., Annunziata, S., Ballesta-Martínez, M., Campeau, P.M., Clayton, P., Eaton, J., Granata, T., Guillén-Navarro, E., Hernando, C., Laverriere, C.E., Liedén, A., Villa-Marcos, O., McEntagart, M., Nordgren, A., Pantaleoni, C., Pébrel-Richard, C., Sarret, C., Sciacca, F., Wright, R., Kerr, B., Glasgow, E., Banka, S. (2016). "Small 6q16.1 Deletions Encompassing POU3F2 Cause Susceptibility to Obesity and Variable Developmental Delay with Intellectual Disability." American Journal of Human Genetics. URL: https://www.semanticscholar.org/paper/8cc1f8fbdd9a04260e561d053a43a3a83cb449a9
[8] Westphal, D., Riedhammer, K., Kovács-Nagy, R., Meitinger, T., Hoefele, J., Wagner, M. (2018). "A De Novo Missense Variant in POU3F2 Identified in a Child with Global Developmental Delay." Neuropediatrics. URL: https://www.semanticscholar.org/paper/f0213715d80e4a41ac0a4d53cf036af13e4895b5
[9] Kobi, D., Steunou, A-L., Dembélé, D., Legras, S., Larue, L., Nieto, L., Davidson, I. (2010). "Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene." Pigment Cell & Melanoma Research. URL: https://www.semanticscholar.org/paper/6ae4673c180c0e66fea9ccde9667aabbc9fb78ce
[10] Song, J., Carter, A.C., Bushinsky, E.M., Beck, S.G., Petrocelli, J.E., Koreman, G.T., Babu, J., Kingsley, D.M., Greenberg, M.E., Walsh, C.A. (2025). "Human-chimpanzee tetraploid system defines mechanisms of species-specific neural gene regulation." bioRxiv. URL: https://www.semanticscholar.org/paper/630a607605fc54f97668c48c9368a2b483205f88
[11] Chitsazan, A., Lambie, D., Ferguson, B., Handoko, H., Gabrielli, B., Walker, G., Boyle, G. (2019). "Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi." Journal of Investigative Dermatology. URL: https://www.semanticscholar.org/paper/ac3fd3d98c0dc7f668dfcd6ac570bfbfbe565f18
[12] Lin, C., Zhang, M., Sun, P., He, Y., Tian, Y., Li, W., Pu, S., Luo, J., Wang, K. (2025). "Proliferation-cycle gene signatures predict immune landscape and prognosis in lung adenocarcinoma." Discover Oncology. URL: https://www.semanticscholar.org/paper/8947bc018e0ea3f2c1a9fdc35a16d2914179c833
[13] Wu, Q., Tao, X., Luo, Y-G., Zheng, S., Lin, N., Xie, X. (2023). "A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer." BMC Cancer. URL: https://www.semanticscholar.org/paper/cd916095968551ddbcc2eff3ee07caa45cf37bc6
[14] Nasu, M., Yada, S., Igarashi, A., Sutoo, D., Akiyama, K., Ito, M., Yoshida, N., Ueda, S. (2014). "Mammalian-Specific Sequences in Pou3f2 Contribute to Maternal Behavior." Genome Biology and Evolution. URL: https://www.semanticscholar.org/paper/7ce3de423a24a72dc51cba568134526315e4cb38
[15] Zhu, X., Guo, Y., Chu, C., Liu, D., Duan, K., Yin, Y., Si, C., Kang, Y., Yao, J., Du, X., Li, J., Zhao, S., Ai, Z., Zhu, Q., Ji, W., Niu, Y., Li, T. (2022). "BRN2 as a key gene drives the early primate telencephalon development." Science Advances. URL: https://www.semanticscholar.org/paper/dc3fc14056b0f2e34665fd1bfe1491f33d9faff9
[16] Swathypriyadharsini, P., Premalatha, K. (2021). "Hybrid Cuckoo Search with Clonal Selection for Triclustering Gene Expression Data of Breast Cancer." Journal of the Institution of Electronics and Telecommunication Engineers. URL: https://www.semanticscholar.org/paper/433e6d9d8546ef45697f9d1e8ffe1050a134776d
[17] Li, H., Chen, J-A., Ding, Q., Lu, G-Y., Wu, N., Su, R-B., Li, F., Li, J. (2020). "Behavioral sensitization induced by methamphetamine causes differential alterations in gene expression and histone acetylation of the prefrontal cortex in rats." BMC Neuroscience. URL: https://www.semanticscholar.org/paper/7ea5ca0d3ea4cd37ec74e8a6a737dbfaf0688bec
[18] Lichtensteiger, W., Bassetti-Gaille, C., Rehrauer, H., Kuhn Georgijevic, J., Tresguerres, J., Schlumpf, M. (2021). "Converging Effects of Three Different Endocrine Disrupters on Sox and Pou Gene Expression in Developing Rat Hippocampus: Possible Role of microRNA in Sex Differences." Frontiers in Genetics. URL: https://www.semanticscholar.org/paper/d9409983ecb38700ea560f55bf787b40dae520f5
[19] Costa, M.D., Teixeira-Castro, A., Constante, M., Magalhães, M., Magalhães, P., Cerqueira, J., Vale, J., Passão, V., Barbosa, C., Robalo, C., Coutinho, P., Bar